18 October 2020 : Clinical Research
Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
Yongxiang Zhang1ABCDE, Yuechuan Li1AEFG*, Zhen Ye1BD, Hui Ma1CFDOI: 10.12659/MSM.925278
Med Sci Monit 2020; 26:e925278
Table 1 Analysis of general information of patients.
| Group | Control (n=20) | COPD (n=40) | P value |
|---|---|---|---|
| Male (n, %) | 13 (65.00%) | 29 (72.50%) | 0.36 |
| Age (years) | 58.05±9.33 | 60.50±4.30 | 1.12 |
| Smoking history (n, %) | 7 (35.0%) | 16 (40.00%) | 0.14 |
| Smoking index | 165.00±153.13 | 167.50±152.56 | 0.06 |
| Emphysema (n, %) | 0 (0.00%) | 25 (62.5%) | NA |
| Pulmonary cancer (n, %) | 18 (90.00%) | 37 (92.50%) | 0.47 |
| Pulmonary hamartoma (n, %) | 1 (5.00%) | 2 (5.00%) | |
| Teratoma (n, %) | 1 (5.00%) | 0 (0.00%) | |
| Pulmonary lipoma (n, %) | 0 (0.00%) | 1 (2.50%) | |
| COPD – chronic obstructive pulmonary disease; DLCO – carbon monoxide diffusing capacity. | |||